JP2013535508A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013535508A5 JP2013535508A5 JP2013524253A JP2013524253A JP2013535508A5 JP 2013535508 A5 JP2013535508 A5 JP 2013535508A5 JP 2013524253 A JP2013524253 A JP 2013524253A JP 2013524253 A JP2013524253 A JP 2013524253A JP 2013535508 A5 JP2013535508 A5 JP 2013535508A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- cancer
- tumor
- virus
- melanoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37376310P | 2010-08-13 | 2010-08-13 | |
| US61/373,763 | 2010-08-13 | ||
| PCT/US2011/047633 WO2012021834A1 (en) | 2010-08-13 | 2011-08-12 | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013535508A JP2013535508A (ja) | 2013-09-12 |
| JP2013535508A5 true JP2013535508A5 (https=) | 2014-09-25 |
Family
ID=45564978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013524253A Pending JP2013535508A (ja) | 2010-08-13 | 2011-08-12 | 抗体付きアジュバントを抗原提示細胞に直接的に標的化することをベースにした新規ワクチンアジュバント |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20120039916A1 (https=) |
| EP (1) | EP2603235A4 (https=) |
| JP (1) | JP2013535508A (https=) |
| KR (1) | KR20130108295A (https=) |
| CN (1) | CN103328005A (https=) |
| AR (1) | AR082686A1 (https=) |
| AU (1) | AU2011289234B2 (https=) |
| BR (1) | BR112013002940A2 (https=) |
| CA (1) | CA2807585A1 (https=) |
| MX (1) | MX2013001527A (https=) |
| RU (1) | RU2013110889A (https=) |
| TW (1) | TWI506035B (https=) |
| WO (1) | WO2012021834A1 (https=) |
| ZA (1) | ZA201301013B (https=) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI422594B (zh) | 2007-02-02 | 2014-01-11 | Baylor Res Inst | 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑 |
| JP2010530735A (ja) * | 2007-05-03 | 2010-09-16 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | 細胞内のｐｒｌ−１ポリペプチドまたはｐｒｌ−３ポリペプチドに結合する抗体 |
| TW201247706A (en) * | 2011-03-08 | 2012-12-01 | Baylor Res Inst | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells |
| WO2013033104A1 (en) * | 2011-08-29 | 2013-03-07 | Baylor Research Institute | CONTROLLING ALLERGY AND ASTHMA BY ACTIVATING HUMAN DCs VIA DECTIN-1 OR DECTIN-1 AND TOLL-LIKE RECEPTOR 2 (TLR2) |
| EP2822599A4 (en) * | 2012-03-05 | 2015-12-23 | Univ Duke | VACCINE FORMULATION |
| CN112587671A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| WO2014031984A1 (en) * | 2012-08-24 | 2014-02-27 | Baylor Research Institute | Immunological detection methods and compositions |
| CA2916694C (en) | 2013-06-28 | 2023-01-17 | Baylor Research Institute | Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis |
| CN103409451A (zh) * | 2013-06-28 | 2013-11-27 | 扬州维克斯生物科技有限公司 | 一种向树突状细胞dc靶向加载肿瘤抗原肽的方法 |
| CA2922937A1 (en) | 2013-09-05 | 2015-03-12 | Duke University | Nav1.7 antibodies and methods of using the same |
| CN105899539B (zh) | 2014-01-10 | 2021-11-09 | 博笛生物科技有限公司 | 用于免疫疗法的化合物和组合物 |
| JP7037884B2 (ja) | 2014-01-13 | 2022-03-17 | ベイラー リサーチ インスティテュート | Ｈｐｖ及びｈｐｖ関連疾患に対する新規のワクチン |
| KR20160106170A (ko) * | 2014-01-22 | 2016-09-09 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체 및 항체-부하된 수지상 세포 매개된 요법을 위한 방법 및 조성물 |
| CN106659774A (zh) | 2014-05-16 | 2017-05-10 | 贝勒研究院 | 用于治疗自身免疫和炎性病症的方法和组合物 |
| EP3148575B1 (en) * | 2014-06-02 | 2019-08-21 | Baylor Research Institute | Compositions for treating allergy and inflammatory diseases |
| BR112016030740A2 (pt) | 2014-07-01 | 2018-02-20 | Pfizer Inc. | diacorpos heterodiméricos biespecíficos e seus usos |
| EP3166976B2 (en) | 2014-07-09 | 2026-04-08 | Birdie Biopharmaceuticals Inc. | Anti-pd-l1 combinations for treating tumors |
| CN112587672A (zh) | 2014-09-01 | 2021-04-02 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
| CN104689313A (zh) * | 2015-03-04 | 2015-06-10 | 中国科学院海洋研究所 | 大菱鲆cd83分子作为疫苗佐剂的应用 |
| WO2016179034A2 (en) * | 2015-05-01 | 2016-11-10 | The Trustees Of The University Of Pennsylvania | Methods and compositions for stimulating immune response using potent immunostimulatory rna motifs |
| TN2018000112A1 (en) | 2015-10-29 | 2019-10-04 | Novartis Ag | Antibody conjugates comprising toll-like receptor agonist |
| HK1259294A1 (zh) * | 2015-11-10 | 2019-11-29 | 耶鲁大学 | 用於治疗自身免疫疾病和癌症的组合物及方法 |
| EP3389707B1 (en) | 2015-12-15 | 2025-08-20 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Immunogenic construct comprising an ebv-cell antigen and a targeting moiety and applications thereof |
| CN106943596A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | 用于治疗肿瘤的抗-cd20组合 |
| CN115252792A (zh) | 2016-01-07 | 2022-11-01 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-egfr组合 |
| CN115350279A (zh) | 2016-01-07 | 2022-11-18 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-her2组合 |
| WO2017152088A1 (en) | 2016-03-04 | 2017-09-08 | JN Biosciences, LLC | Antibodies to tigit |
| KR102726248B1 (ko) | 2016-07-07 | 2024-11-05 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
| WO2018140831A2 (en) * | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| CN108727503A (zh) * | 2017-04-18 | 2018-11-02 | 武汉博沃生物科技有限公司 | VZV重组gE-鞭毛素融合蛋白及其制备方法和应用 |
| CN118515666A (zh) | 2017-04-27 | 2024-08-20 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
| IL312120B2 (en) | 2017-06-23 | 2025-06-01 | Birdie Biopharmaceuticals Inc | Pharmaceutical compositions |
| EP3645043A4 (en) * | 2017-06-28 | 2021-04-07 | The Board of Trustees of the Leland Stanford Junior University | METHODS AND COMPOSITIONS FOR DECTIN 2 STIMULATION AND CANCER IMMUNOTHERAPY |
| US20210369635A1 (en) * | 2017-11-29 | 2021-12-02 | Adaptive Phage Therapeutics, Inc. | Novel methods of vaccination using icosahedral phage |
| RU2020131012A (ru) * | 2018-02-28 | 2022-03-28 | Ф. Хоффманн-Ля Рош Аг | 7-замещенные соединения сульфонимидоилпуринонов и их производные для лечения и профилактики рака печени |
| US12589140B2 (en) | 2019-01-22 | 2026-03-31 | The Brigham And Women's Hospital, Inc. | Antigen-presenting neutrophil-derived dendritic cells and methods of use thereof |
| AU2020241686A1 (en) | 2019-03-15 | 2021-11-04 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
| EP3947454A1 (en) | 2019-03-27 | 2022-02-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Recombinant proteins with cd40 activating properties |
| WO2020243616A1 (en) * | 2019-05-31 | 2020-12-03 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | E-cadherin activating antibodies and uses thereof |
| JP2023502712A (ja) * | 2019-11-21 | 2023-01-25 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） | 抗ｐｄ－１／ｉｌ－１５免疫サイトカインによる新しいｐｄ－１標的免疫療法 |
| JP7735291B2 (ja) | 2020-02-21 | 2025-09-08 | エーアールエス ファーマシューティカルズ、インコーポレイテッド | ネクチン－４抗体コンジュゲートおよびその使用 |
| JP2023525140A (ja) | 2020-05-13 | 2023-06-14 | アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） | Ｏｘ４０活性化特性を有する組換えタンパク質 |
| WO2021239838A2 (en) | 2020-05-26 | 2021-12-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes |
| BR112022024221A2 (pt) | 2020-06-02 | 2022-12-20 | Arcus Biosciences Inc | Anticorpos para tigit |
| JP2023532304A (ja) | 2020-07-01 | 2023-07-27 | エーアールエス ファーマシューティカルズ オペレーションズ，インク． | 抗ａｓｇｒ１抗体コンジュゲートおよびその使用 |
| CN111850006B (zh) * | 2020-07-27 | 2022-04-22 | 齐鲁工业大学 | 一种适用于低钙离子浓度的纤维小体对接蛋白组合突变体36865及应用 |
| CA3200878A1 (en) | 2020-11-12 | 2022-05-19 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Antibodies conjugated or fused to the receptor-binding domain of the sars-cov-2 spike protein and uses thereof for vaccine purposes |
| JP2023549555A (ja) * | 2020-11-18 | 2023-11-27 | パイオニア イミュノセラピューティクス インコーポレイテッド | 抗ｍａｒｃｏ抗体及びその使用 |
| EP4267176A1 (en) | 2020-12-23 | 2023-11-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Chlamydia vaccine based on targeting momp vs4 antigen to antigen presenting cells |
| CA3209251A1 (en) | 2021-01-29 | 2022-08-04 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Chlamydia trachomatis antigenic polypeptides and uses thereof for vaccine purposes |
| WO2023081806A2 (en) * | 2021-11-04 | 2023-05-11 | The General Hospital Corporation | Anti-mesothelin antibody reagents |
| KR20240103030A (ko) | 2021-11-17 | 2024-07-03 | 인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰 메디칼르 | 범용 사르베코바이러스 백신 |
| WO2024074571A1 (en) | 2022-10-05 | 2024-04-11 | Institut National de la Santé et de la Recherche Médicale | Dc-targeting vaccine against nipah virus infection |
| EP4601682A1 (en) * | 2022-10-13 | 2025-08-20 | The Brigham & Women's Hospital, Inc. | Methods and compositions for improving response to immunotherapy |
| KR102878250B1 (ko) * | 2023-01-11 | 2025-10-31 | 서울대학교산학협력단 | 코리스메이트 뮤테이즈 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 포함하는 암 예방 또는 치료용 조성물 |
| WO2024216189A1 (en) * | 2023-04-13 | 2024-10-17 | The Regents Of The University Of California | Isoform-independent antibodies to lipoprotein(a) |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1057915C (zh) * | 1994-09-19 | 2000-11-01 | 中国医学科学院医药生物技术研究所 | 免疫佐剂 |
| TW200303759A (en) * | 2001-11-27 | 2003-09-16 | Schering Corp | Methods for treating cancer |
| US9259459B2 (en) * | 2003-01-31 | 2016-02-16 | Celldex Therapeutics Inc. | Antibody vaccine conjugates and uses therefor |
| WO2007103048A2 (en) * | 2006-03-01 | 2007-09-13 | Regents Of The University Of Colorado | Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity |
| US20070224205A1 (en) * | 2006-03-07 | 2007-09-27 | Powell Thomas J | Compositions that include hemagglutinin, methods of making and methods of use thereof |
| KR20090114430A (ko) * | 2007-02-02 | 2009-11-03 | 베일러 리서치 인스티튜트 | 항원-제시 세포 상에서 발현된 ｄｃｉｒ에 대한 항원 표적화에 기초한 백신 |
| MX2009008926A (es) * | 2007-02-23 | 2009-09-14 | Baylor Res Inst | Aplicaciones terapeuticas de activacion de celulas que presentan antigeno humano por medio de detectina a-1. |
| NZ599777A (en) * | 2007-11-07 | 2013-09-27 | Celldex Therapeutics Inc | Antibodies that bind human dendritic and epithelial cell 205 (DEC-205) |
| CA2730742C (en) * | 2008-07-16 | 2017-05-23 | Baylor Research Institute | Hiv vaccine based on targeting maximized gag and nef to dendritic cells |
| AU2010222928B2 (en) * | 2008-07-16 | 2012-11-29 | Baylor Research Institute | Antigen presenting cell targeted vaccines |
| DK2406286T3 (en) * | 2009-03-10 | 2016-08-22 | Baylor Res Inst | Anti-cd40 antibodies and uses thereof |
| EP2406289B1 (en) * | 2009-03-10 | 2017-02-22 | Baylor Research Institute | Antigen presenting cell targeted anti-viral vaccines |
| MX2012012833A (es) * | 2010-05-07 | 2012-11-30 | Baylor Res Inst | Cebado cruzado de celulas t cd8 positivas humanos moderada por inmunoreceptores de celulas dendriticas (dcir). |
-
2011
- 2011-08-12 BR BR112013002940A patent/BR112013002940A2/pt not_active IP Right Cessation
- 2011-08-12 KR KR1020137006354A patent/KR20130108295A/ko not_active Withdrawn
- 2011-08-12 MX MX2013001527A patent/MX2013001527A/es not_active Application Discontinuation
- 2011-08-12 AR ARP110102955A patent/AR082686A1/es not_active Application Discontinuation
- 2011-08-12 AU AU2011289234A patent/AU2011289234B2/en not_active Ceased
- 2011-08-12 US US13/208,993 patent/US20120039916A1/en not_active Abandoned
- 2011-08-12 CA CA2807585A patent/CA2807585A1/en not_active Abandoned
- 2011-08-12 EP EP11817128.9A patent/EP2603235A4/en not_active Withdrawn
- 2011-08-12 RU RU2013110889/10A patent/RU2013110889A/ru unknown
- 2011-08-12 WO PCT/US2011/047633 patent/WO2012021834A1/en not_active Ceased
- 2011-08-12 JP JP2013524253A patent/JP2013535508A/ja active Pending
- 2011-08-12 CN CN2011800489046A patent/CN103328005A/zh active Pending
- 2011-08-12 TW TW100128970A patent/TWI506035B/zh not_active IP Right Cessation
-
2013
- 2013-02-06 ZA ZA2013/01013A patent/ZA201301013B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013535508A5 (https=) | ||
| RU2013110889A (ru) | Новые вакцинные адъюванты на основе адъювантов-антител, нацеливающих непосредственно на антигенпрезентирующие клетки | |
| RU2012152828A (ru) | Опосредованное иммунорецепторами дендритных клеток (dcir) перекрестное примирование cd8+ т клеток человека | |
| US20120231023A1 (en) | Novel Vaccine Adjuvants Based on Targeting Adjuvants to Antibodies Directly to Antigen-Presenting Cells | |
| TWI423985B (zh) | 利用ｄｅｃｔｉｎ-１活化人類抗原呈現細胞之醫療應用 | |
| JP6952029B2 (ja) | Ｔ細胞療法用のｔ細胞を調製する方法 | |
| TWI446921B (zh) | 基於表現於抗原-表現細胞之樹突細胞免疫受體（ｄｃｉｒ）之標的抗原之疫苗 | |
| US20120121592A1 (en) | Targeting Antigens to Human Dendritic Cells Via DC-Asialoglycoprotein Receptor to Produce IL-10 Regulatory T-Cells | |
| WO2004027049B1 (en) | Methods and compositions to generate and control the effector profile of t cells by simultaneous loading and activation of selected subsets of antigen presenting cells | |
| TW200846370A (en) | Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR) | |
| JP2015071598A5 (https=) | ||
| JP2017508797A (ja) | Ｔエフェクター細胞の調節性ｔ細胞に対する比を増加するための方法および組成物 | |
| JP2001524928A (ja) | クロスプライミング免疫による天然抗原に特異性を有するｃｔｌの誘導 | |
| Cohen et al. | CD4+ T-cells from mice immunized to syngeneic sarcomas recognize distinct, non-shared tumor antigens | |
| CN113797332B (zh) | 用于免疫疗法的组合物和方法 | |
| RU2013121571A (ru) | Композиции и способы профилактики и лечения злокачественных новообразований | |
| CA2830987A1 (en) | Dendritic cells (dcs) targeting for tuberculosis (tb) vaccine | |
| Jemon et al. | An enhanced heterologous virus-like particle for human papillomavirus type 16 tumour immunotherapy | |
| Sokke Umeshappa et al. | CD154 and IL-2 signaling of CD4+ T cells play a critical role in multiple phases of CD8+ CTL responses following adenovirus vaccination | |
| EP4719469A1 (en) | Combination containing an mrna vaccine or an mrna encoded therapeutic protein and an immune modulating mrna for improved or reduced immunogenicity to increase efficacy | |
| US20260091112A1 (en) | Vaccine comprising peripheral blood mononuclear cells loaded with natural killer t cell ligand and antigen | |
| Park | Vaccine strategies utilizing C-type lectin receptors on dendritic cells in vivo | |
| JP2023539525A (ja) | 抗体療法 | |
| RU2856462C2 (ru) | Вакцина, содержащая мононуклеарные клетки периферической крови, нагруженные лигандами естественных t-клеток-киллеров и антигенами | |
| RU2420311C2 (ru) | Вакцина на основе в-клеток, нагруженных лигандом т-клеток-природных киллеров и антигеном |